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ABSTRACT
This review describes the methods available for drug susceptibility testing of Mycobacterium tuberculosis.
The methods have been developed over several decades and are restricted to specialised centres in most
European countries, as they are technically demanding, require appropriate isolation facilities and can
be difﬁcult to interpret. The absolute concentration, resistance ratio and proportion methods can all give
accurate results, provided that they are carefully quality-controlled and standardised. Automated rapid
culture and molecular methods have been evaluated at large reference centres and in multicentre
collaborations, and perform well for testing susceptibility to most ﬁrst- and second-line anti-tuberculosis
drugs. Accuracy is more important than rapid testing, and this is most reliably achieved if drug
susceptibility tests are done in a small number of well-equipped, experienced laboratories that
participate and perform well in an international drug susceptibility testing quality assessment scheme.
The WHO Supranational Laboratory Quality Control Network offers a global scheme that assesses the
ability of participating laboratories to identify isoniazid, rifampicin, ethambutol and streptomycin
resistance. Second-line drug resistance testing is currently being standardised, and such testing should
only be performed at the national reference laboratories in western and central European countries
because of the relatively small number of cases and the concomitant difﬁculty of maintaining testing
proﬁciency in multiple centres performing small numbers of tests. There is a need to expand
international external quality assessment to include second-line drug susceptibility testing.
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INTRODUCTION
Tuberculosis (TB) is one of the commonest infec-
tious diseases in the world today, with over
8 million new cases and 2 million deaths occur-
ring annually [1–5]. More than 95% of cases occur
in the developing world, and TB can cause c. 25%
of all avoidable adult deaths from infection [6].
The steady decline in the number of cases of
clinical TB in the developed world, as well as in
parts of the developing world, ceased or reversed
during the mid-1980s. Case rates rose in the USA,
particularly in New York, and throughout much
of western Europe [3,7–10]. TB notiﬁcations have
continued to increase globally, particularly in
Africa and Asia, but also in many eastern Euro-
pean countries of the former Soviet Union. In
western Europe, these trends mainly reﬂect the
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migration of individuals from countries with a
high incidence of TB and, in some settings,
infection with human immunodeﬁciency virus
(HIV). However, the increasing rates of TB in
eastern Europe reﬂect problems in national con-
trol programmes as a consequence of rapid
political transitions, non-standard treatment strat-
egies, and socio-economic crises [2,3,5,11]. The
highest estimated incidence and mortality rates
occur in sub-Saharan Africa and southeast Asia.
In contrast, mortality rates are generally
<2 ⁄ 100 000 population in the industrialised parts
of Europe, America and Australasia [1,2].
DRUG-RESISTANT TB
The real level of drug resistance in the world
today is unknown, although national and regional
studies and anecdotal evidence indicate that it has
been increasing in recent years [12–19]. In partic-
ular, multiple drug-resistant TB (MDRTB) contin-
ues to be a serious problem, especially in
developing countries in Asia [12], the Baltic
region [20–22] and other parts of the former
Soviet Union [23–28].
Analysis of drug susceptibility of Mycobacte-
rium tuberculosis strains is essential: (i) for sur-
veillance; (ii) to inﬂuence the development of
treatment guidelines; (iii) to guide the clinical
management of cases with proven resistance to
ﬁrst-line drugs and individuals with epidemio-
logical risk-factors for drug resistance; (iv) to
determine the type of hospital or the need for
institutional isolation of patients; and (v) to
determine the scope of institutional and commu-
nity outbreak investigations required.
Landmark trials conducted by the UK Medical
Research Council and others have established the
therapeutic efﬁcacy of current multidrug regi-
mens, taken for periods of 6–12 months, depend-
ing on the location of disease. Cure rates in excess
of 95% are possible, but the effectiveness of these
standardised regimens is compromised when
drugs are taken inappropriately because of poor
patient compliance [29–34]. There have been few
truly novel antimicrobial agents identiﬁed in
recent years [35]. Morbidity and mortality rates
are higher for drug-resistant cases, particularly if
the organisms involved aremultiple drug-resistant
(i.e., resistant to isoniazid or rifampicin) [36] and
there is co-infection with HIV [37–41]. Recent
studies have demonstrated that survival can be
improved by the rapid initiation of treatment
with drugs to which the organism is susceptible
[41–48].
The emergence of MDRTB has re-focused
attention on TB as a disease of continuing signif-
icance in the developed and developing world.
Unfortunately, several methodological problems
have prevented the development of a clear global
picture, including the absence of adequate culture
facilities, the use of non-standardised methodol-
ogies, the absence of quality control measures, the
absence of longitudinal studies to detect trends,
the failure of some studies to differentiate
between primary and acquired drug resistance,
and the inherent selection bias of many surveys,
particularly those centred on large studies and
specialised hospitals.
GLOBAL ANALYSIS OF DRUG
RESISTANCE
In 1994, the WHO and the International Union
Against Tuberculosis and Lung Disease initiated
the Global Project on Anti-tuberculosis Drug
Resistance Surveillance [15,16]. This project was
designed to measure the prevalence of resistance
according to standardised methods, guided by
three overriding principles: (i) that the sample of
TB patients must be representative of cases within
an entire country; (ii) that laboratory performance
is validated; and (iii) that primary and acquired
drug resistance can be distinguished. In the recent
third report of this project, data collected between
1999 and 2002 from 77 settings or countries,
representing 20% of the global total of new
smear-positive TB cases, were presented [16].
Data concerning new cases were available for 75
settings and 55 779 patients. The prevalence of
resistance to at least one anti-TB drug (any
resistance) ranged from 0% in some western
European countries to 57.1% in Kazakhstan
(median 10.2%). Median frequencies of resistance
to speciﬁc drugs were streptomycin 6.3%, isoni-
azid 5.9%, rifampicin 1.4% and ethambutol 0.8%.
The prevalence of multiple drug resistance (MDR)
ranged from 0% in eight countries to 14.2% in
Kazakhstan (51 ⁄ 359) and Israel (36 ⁄ 253) (median
1.1%). The highest frequencies of MDR were
observed in Tomsk Oblast (Russian Federation)
(13.7%), Karakalpakstan (Uzbekistan) (13.2%),
Estonia (12.2%), Liaoning Province (China)
(10.4%), Lithuania (9.4%), Latvia (9.3%), Henan
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Province (China) (7.8%) and Ecuador (6.6%).
Trends in drug resistance among new cases were
determined in 46 settings (20 with two data points
and 26 with at least three). Signiﬁcant increases in
the prevalence of any resistance were found in
Botswana, New Zealand, Poland and Tomsk
Oblast (Russian Federation), while Cuba, the
Hong Kong Special Administrative Region and
Thailand reported signiﬁcant decreases over time.
Tomsk Oblast (Russian Federation) and Poland
reported a signiﬁcantly increased prevalence of
MDR, while decreasing trends were observed in
the Hong Kong Special Administrative Region,
Thailand and the USA.
Data concerning previously treated cases were
available for 66 settings. In total, 8405 patients
were surveyed. The median prevalence of resis-
tance to at least one drug (any resistance) was
18.4%, with the highest prevalence being 82.1%
in Kazakhstan (262 ⁄ 319). Median frequencies of
resistance to speciﬁc drugs were isoniazid 14.4%,
streptomycin 11.4%, rifampicin 8.7% and etham-
butol 3.5%. The median prevalence of MDR was
7.0%. The highest frequencies of MDR were
reported in Oman (58.3%; 7 ⁄ 12) and Kazakhstan
(56.4%; 180 ⁄ 319). Among countries of the former
Soviet Union, the median prevalence of resistance
to these four drugs was 30%, compared with a
median of 1.3% in all other settings [16]. Given
the small number of subjects tested in some
settings, the prevalence of resistance among cases
treated previously should be interpreted with
caution. The use of standardised short-course
chemotherapy was associated with a lower level
of drug resistance. The recent emergence of
extensively drug-resistant tuberculosis (resistance
to isoniazid, rifampicin, any ﬂuoroquinolone and
amikacin or kanamycin or capreomycin) has
caused a high mortality, particularly in indivi-
duals co-infected with HIV [17,18]. The properties
and recommended doses of the principal anti-TB
drugs that are currently available are summarised
in Table 1.
SUPRANATIONAL REFERENCE
LABORATORY NETWORK
A key part of the Global Programme (see above)
was the creation of a Global Network of Suprana-
tional Reference Laboratories (SRLs) to serve as
reference centres for external quality assess-
ment ⁄ control (EQA) of drug susceptibility testing
in national surveys. Several annual EQA distribu-
tions, focusing on resistance to isoniazid,
rifampicin, ethambutol and streptomycin, have
been completed by the network. There is no EQA
for pyrazinamide at present, reﬂecting the difﬁ-
culty in reliably and consistently measuring resis-
tance to this agent.
In each EQA distribution, identical sets of ten
isolates of M. tuberculosis (20 cultures in early
distributions, 30 cultures in recent distributions)
were distributed to all SRLs. This sample size was
calculated to yield a signiﬁcance level of 95% in
order to detect true differences among laboratory
methods with a power of 90% [15,16,49]. In turn,
the SRLs supported national surveys or ongoing
surveillance in their own countries, and also
supported national reference laboratories world-
wide in conducting surveys with the national TB
programme. Regional networks of laboratories
were formed in the Western Paciﬁc Region and in
Europe, coordinated by the SRLs in London (UK),
Stockholm (Sweden), Paris (France) and Borstel
(Germany).
European countries have various degrees of
centralisation of facilities for measuring drug
resistance. For example, most hospital laborato-
ries in England submit isolates of M. tuberculosis
and other mycobacteria to the Health Protection
Agency Mycobacterium Reference Unit, or to one
of the other Regional Centres for Mycobacteriol-
ogy, for speciation and drug susceptibility testing.
A system for the surveillance of drug resistance in
isolates of M. tuberculosis, i.e., the UK Mycobacte-
rial Resistance Network (Mycobnet), was estab-
lished in 1993–1994 to link the principal reference
units in the UK. In initial studies, isoniazid and
rifampicin resistance rose from 4.6% (157 cases)
to 6.1% (221 cases), and from 0.6% (22 cases) to
1.8% (65 cases), respectively, between 1993 and
1996 [19]. Initial MDRTB rates in the same period
increased from 0.6% to 1.6%, and combined
clinical resistance or period prevalence (the total
level of resistance occurring in 1 year) rose from
0.6% to 1.7% [17,50]. In 2003, susceptibility test
results with isoniazid and with rifampicin for
4928 isolates (99.7% of the actual total), obtained
from cases at the start of treatment, revealed that
388 (7.9%) were resistant to one or more of the
ﬁrst-line drugs; 346 isolates (7.0%) were isonia-
zid-resistant and 68 (1.4%) were MDR (UK
Mycobnet, http://www.hpa.org.uk/infections/
topics_az/tb).
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In general, drug-resistant cases of TB were
more likely to be seen among males, individuals
who were previously TB-positive or who were
HIV-positive (biased by outbreaks), those born
abroad and those in the black African ethnic
group (rates were lowest among the white ethnic
group). Drug-resistant cases, by trend and abso-
lute numbers, were identiﬁed predominantly in
London. Similar risk-factors apply in respect of
increases in the incidence of TB seen in other west
European countries.
MEASURING DRUG RESISTANCE IN
M. TUBERCULOSIS
Drug resistance occurs spontaneously inM. tuber-
culosis at a different rate for each drug. For
example, mutations resulting in resistance to
rifampicin occur at a rate of 10)10 ⁄ cell division,
compared with 10)7)10)9 for isoniazid. Overall,
this creates an estimated frequency of resistant
organisms in drug-free environments of 1 in 108
and 1 in 106, respectively, for the two drugs [51].
As lung cavities frequently contain 107 bacilli,
resistant bacilli emerge naturally without anti-
microbial pressure, and the use of anti-mycobac-
terial drugs then selects the resistant population
[30,33,51]. By the 1950s, it was established that
combination chemotherapy could prevent the
emergence of clinical resistance that was observed
when patients were treated with a single drug.
Today, mono-drug therapy effectively occurs only
when inappropriate chemoprophylaxis or treat-
ment is given, or in cases where there is poor
adherence to therapy, an irregular drug supply or
drug malabsorption [52].
The lack of uniformity and reproducibility in
the methods used for testing susceptibility to anti-
TB drugs was ﬁrst noted in the late 1950s and
1960s. Thus, for isoniazid, at least eight criteria
were used to deﬁne resistance. In studies
that examined the major susceptibility testing
Table 1. Front-line anti-tuberculosis drugs for adults
Drug Routea Daily doseb Intermittent twice-weekly Three times weekly Major side-effectsc Monitoringd
Isoniazid PO
IM
IV
300 mg
5 mg ⁄ kg
15 mg ⁄ kg
max. = 900 mg
15 mg ⁄ kg
max. = 900 mg
Peripheral neuropathy,
hepatitis, CNS effects,
increased phenytoin
levels, interaction
with disulphiram,
hepatic enzyme
elevation
LFT; levels of
interacting
drugse
Rifampicin PO
IV
600 mg
10 mg ⁄ kg
10 mg ⁄ kg
max. = 600 mg
10 mg ⁄ kg
max. = 600 mg
GI upset, hepatitis,
rash, bleeding,
contact lens
and body ﬂuids
coloured orange ⁄pink;
decreases serum levels
of warfarin, methadone,
contraceptive hormones,
dapsone, ketoconazole
and theophylline;
inﬂuenza-like syndrome
LFT; levels of
interacting
drugs
Pyrazinamide PO 1.5–2.5 g
15–30 mg ⁄ kg
2.5–3.5 g
50–70 mg ⁄ kg
2–3 g
50–70 mg ⁄ kg
GI upset, increase in
hepatic enzyme levels,
rash, joint pain,
hyperuricaemia (gout
rarely); may complicate
control of diabetes
mellitus
LFT; uric acid
(if needed)
Ethambutol PO 2.5 g (max.)
15–25 mg ⁄ kg
50 mg ⁄ kg 30 mg ⁄ kg Red ⁄ green colour
blindness, optic
neuritis, decreased
visual activity, rash
Colour vision,
visual acuity
Streptomycinf IM
IV
15 mg ⁄ kg 25–30 mg ⁄ kg 25 mg ⁄ kg Nephrotoxicity,
ototoxicity,
hypokalaemia,
hypomagnesaemia
Blood chemistry,
renal function,
audiometry
PO, oral; IM, intramuscular; IV, intravenous; CNS, central nervous system; GI, gastrointestinal.
aPossible routes of administration; in practice, all drugs are given orally wherever possible.
bThe daily dose is quoted for an adult male of average weight; all doses are adjusted in accordance with a patient’s weight.
cIsoniazid causes increased elimination of pyridoxine, leading to peripheral neuropathy, particularly in alcoholics, in the malnourished, and during pregnancy. Daily doses of
10 mg ⁄day are sufﬁcient to compensate for this loss.
dLFT, liver function test; speciﬁc monitoring points are given. At appropriate intervals, the patient should be monitored clinically, radiologically and bacteriologically. A full
blood count including platelets should be performed if there is any bleeding tendency.
eAluminium-based antacids reduce absorption.
fStreptomycin in patients aged >60 years is more likely to lead to side-effects, and daily doses should be limited to 10 mg ⁄ kg, with a maximum dose of 750 mg. Closer
observation of hearing loss and renal function may be necessary in this age group.
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methods available at the time, signiﬁcant differ-
ences were noted in the media used, the inoculum
size, the minimum concentrations of drug tested,
and the criteria used to establish resistance.
Symposia organised by the WHO and the Inter-
national Union Against Tuberculosis produced
agreed deﬁnitions for drug resistance, and three
categories of acceptable methods were deﬁned:
(1) the absolute concentration method (effectively
the MIC);
(2) the resistance ratio method;
(3) the proportion method.
Detailed descriptions of these methods have
been published for ﬁrst- and second-line drugs
[53–61]. These documents form the bedrock of
drug susceptibility testing for M. tuberculosis
internationally. The performance of drug suscep-
tibility tests in a limited number of expert centres
is necessary, as getting the right result is difﬁcult
(requiring good standard operating procedures,
internal and external quality control systems and
proﬁciency testing). The WHO Global Network of
SRLs was established to act as a quality control
network and to maintain a high level of proﬁ-
ciency in the diagnosis of drug-resistant TB. In
practice, all three principal methods can perform
adequately, provided that the technical protocols
published are followed exactly [15,16,57].
The absolute concentration method
Drug is incorporated into solid agar or Lowen-
stein–Jensen medium as two-fold dilutions, or is
used in a broth dilution method. Solid media
methods are standardised more easily. Resistance
is deﬁned as the lowest concentration of the drug
that inhibits growth (<20 colonies). Drug concen-
trations, and particularly inoculum size, must be
carefully standardised with reference to wild-type
cultures. Variation in inoculum size is the major
source of error in this method [57,60].
The resistance ratio method
This is a reﬁnement of the absolute concentration
method, in which variations in the MIC for a
given isolate are controlled when the isolate is
tested on different batches of drug-containing
medium. The resistance ratio is deﬁned as the
MIC for the test isolate divided by the MIC for a
standard susceptible strain, e.g., H37Rv, or for
recently isolated susceptible wild-type strains. If
the ratio is 2 or less, or 8 or more, the isolate is
fully susceptible or highly resistant, respectively.
Intermediate or low-level resistance is difﬁcult to
measure accurately [53,54,57]. Inoculum size
needs to be standardised, but the critical concen-
tration does not need to be determined because of
the direct comparison with susceptible isolates
[57].
Proportion method
In this method, the strain is classiﬁed as suscep-
tible if its constituent cell population contains
below a critical proportion of resistant cells, and
as resistant if above this proportion. The propor-
tion varies with different drugs, e.g., 1% for
isoniazid and rifampicin. This correlates with an
effective clinical outcome. In practical terms, the
proportion of drug-resistant mutants is obtained
from the ratio of the number of colonies growing
on drug-containing medium and on drug-free
medium [53,54,60].
The introduction of the broth-based radiometric
BACTEC 460 system led to the development of the
proportion method for use with this system, using
the ratio of growth indices obtained by inoculation
of the test isolate in drug-containing medium and
inoculation of a 100-fold dilution (1%) of the isolate
in drug-free medium [61,62]. Standardisation of
the inoculum is not as critical in this method,
although individual colonies must be visible when
using solid media.
Rapid, non-radiometric, automated culture
methods
In addition to these three accepted methods,
rapid, non-radiometric, automated methods
have been used increasingly for diagnostic
culture, and studies using these systems to
determine resistance to isoniazid and rifampi-
cin, as well as to other ﬁrst-line drugs, have
been published [63–77]. Their use is likely to
increase, but mainly only in large reference
centres because of the higher cost as compared
with solid culture-based methods. All of these
systems use a modiﬁcation of the proportion
method. Most studies have utilised indirect
assays (i.e., on cultured bacteria), with greatest
success for the determination of isoniazid and
rifampicin resistance. However, smear-positive
material can be analysed in direct assays on
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solid media, and this may be almost as fast as
indirect assays and is less expensive. The capital
costs of automated systems are high, and
laboratory containment facilities must be of the
highest order, which increases the cost even
further.
The use of such systems for second-line drug
susceptibility testing has only recently been
explored, and it appears that the WHO 2001
guidelines concerning second-line drug suscepti-
bility testing [59] may have been premature, as a
subsequent multicentre analysis concluded that
results obtained for second-line drug susceptibil-
ity testing were not reliable [74]. An earlier
multicentre study, employing the BACTEC 460
system, demonstrated consistency for a range of
second-line drugs [75], but until recently, there
had been no comparative study of the MGIT 960
system and solid media-based methods, such as
the resistance ratio or proportion methods. These
studies have now been completed [72,76], with
good correlation for most, but not all, second-line
drugs between the solid medium-based resistance
ratio and proportion methods and the MGIT 960
system.
Other methods have been explored for use in
early bactericidal assays as surrogates for the
above methods, with some success [78–80]. Inter-
national quality assessment programmes for
second-line drug testing are now being developed
[81] and the WHO guidelines [59] are under
revision and will be released in late 2007.
MOLECULAR METHODS FOR
DETECTING DRUG RESISTANCE
Novel molecular assays for detecting drug resis-
tance offer several potential advantages, including
lower turnaround times and minimal (or possibly
no) initial culture. Many of the key gene mutations
conferring resistance have been identiﬁed, permit-
ting the development of in-house and commercial
molecular tests [82–99]. Considerable problems
remain in the development of tests for clinical use.
The majority of these tests are more costly than
current methods, the exact ratio of resistant to
susceptible organisms that produces clinical resis-
tance is unclear, and the presence of common gene
mutations is not always associated with drug
resistance (i.e., silent mutations). Nevertheless,
the mutations associated with resistance are now
well-known for some drugs. Novel non-culture-
based drug resistance tests can be divided into
genotypic systems, in which the drug target and
nature of the gene mutation is known, and pheno-
typic systems, in which an outcome (i.e., death of
the bacillus) is measured and previous knowledge
of the precise underlying resistance mechanism is
not required.
Realistically, a combination of both types of test
is required. Mutations within an 81-bp region
(codons 507–533) of the rpoB gene, encoding the
b chain of the DNA-dependent RNA polymerase,
confer rifampicin resistance in c. 90–95% of all
clinical isolates examined [86–89,91,93–105]. The
presence of a mutation can be detected by a
genotypic test and, in nearly all cases, is predic-
tive of clinical drug resistance. However, isonia-
zid drug resistance is more complex, involving
mutations in at least four genes or gene
complexes, with not all mutations affecting the
phenotype [82,84,85,87,91,92,96,97,103–105]. Insuf-
ﬁcient information concerning the mechanism(s)
of resistance means that although the best geno-
typic systems will predict rifampicin resistance in
90–95% of isolates, they would currently fail to
predict streptomycin, isoniazid and ciproﬂoxacin
resistance in c. 40%, 10–15% and 25% of isolates,
respectively. Known or postulated genes involved
in drug resistance are listed in Table 2.
Most genotypic assays involve three main
steps: (i) sample preparation, which may be as
simple as mechanical disruption by boiling a
small volume of cells in water, or may involve full
DNA puriﬁcation; (ii) ampliﬁcation of a speciﬁc
region of a gene; and (iii) detection of the
mutation. Once appropriate primers have been
selected, the region of interest can be ampliﬁed
and mutations detected as described below.
DNA sequencing and other rapid molecular
genotyping assays
DNA sequencing is the reference standard, as all
mutations will be detected and, unless they are
silent, will be predictive of resistance. Automation
has simpliﬁed the process, bringing sequencing
within the capability of large academic and
reference centres, although automated analysers
are relatively expensive to purchase and operate.
Automated analysers using ﬂuorescent chemistry
methods can provide accurate sequence data
within 48 h. As indicated in Table 2, automated
sequencing has been used in both research and
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clinical settings to identify mutations for resis-
tance to most ﬁrst-line TB drugs.
Microarrays and macroarrays using a solid-
phase hybridisation approach offer an alternative
approach to direct sequencing as part of initial
screens for mutations (see below). Other alterna-
tive techniques for mutation identiﬁcation include
PCR single-strand conformation polymorphism
analysis [89], heteroduplex analysis [90], pyrose-
quencing (a short-read sequencing assay devel-
oped and applied as a screen to detect common
mutations in katG and rpoB in early cultures) [92],
mutation-speciﬁc priming, and restriction enzyme
analysis. These methods are generally PCR-based,
with ampliﬁcation of the key regions involved in
drug resistance being followed by a method that
detects wild-type sequences or mutations in the
ampliﬁed fragments.
Solid-phase hybridisation: microarrays and
macroarrays
Using knowledge of the sequence in susceptible
and resistant strains, it is possible to design probes
that can be immobilised on a membrane support.
Resistance can then be detected by a reverse
hybridisation principle [23,99–105]; i.e., a region
of DNA that contains mutations associated with
drug resistance can be ampliﬁed and allowed to
hybridise with the probes. Failure of hybidisation
is caused by the presence of amutation, and thus is
predictive of drug resistance.
Microarrays are high-density oligonucleotide
arrays. An initial PCR produces ﬂuorescently
labelled DNA fragments which, when hybridised
to the corresponding sequence on the microarray,
emit a ﬂuorescent signal that is detected by a
scanner. This technique has been applied to the
identiﬁcation of mycobacteria [98,106,107] and to
the detection of drug resistance. The latter results
were in concordance with those obtained by
sequencing of the katG, inhA (isoniazid resis-
tance), rpoB, rpsL and gyrA genes. Eventually,
these techniques should enable the simultaneous
detection, identiﬁcation, susceptibility proﬁling
and assessment of the probable virulence of a
strain, but costs are high, and the approach is
limited by the current extent of knowledge relat-
ing to the mechanisms of resistance for many of
these drugs.
There have been several reports concerning the
use of commercial macroarrays with cultures
[23,100–105]. For example, in an initial evaluation
in the UK, 100% (16 ⁄ 16) of rifampicin-resistant
cultures were identiﬁed correctly by the Innolipa
assay [100]. This assay has also been used suc-
cessfully to analyse rifampicin resistance directly
in primary specimens [100–102]. In a retrospective
follow-up study of 2287 consecutive specimens
from 2110 patients, performed between 1 January
1999 and 31 December 2002, the overall concor-
dance, sensitivity, speciﬁcity, positive predictive
value and negative predictive value for TB diag-
nosiswere 91.2%, 85.2%, 96.2%, 95.7% and 86.7%,
Table 2. Molecular detection of
drug resistance in Mycobacterium
tuberculosis
Drug
Known or
probable targets
Mutations in genes
conferring resistance Function of gene
Molecular
assays
Rifampicin RNA synthesis rpoB DNA-dependent RNA
polymerase (b subunit)
PCR-SSCP,
heteroduplex,
microarray,
macroarray,
line probe,
sequencing
Isoniazid Mycolic acid
biosynthesis
katG
inhA ⁄mabA
ahpC
Catalase ⁄peroxidase
Fatty-acid biosynthesis
Alkylhydroperoxide C
reductase
PCR-SSCP,
microarray,
macroarray,
sequencing
oxyR Oxidative stress regulator
Streptomycin Protein
synthesis
rrs
rpsl
16S rRNA
ribosomal protein S12
PCR-SSCP,
microarray
sequencing
Ethambutol Cell wall
synthesis
embA,B,C Lipoarabinomannan and
arabinogalactan synthesis
Sequencing
Ethionamide Cell wall
synthesis
inhA + ? Cross-resistance
associated with
inhA mutations
Sequencing
Pyrazinamide Pyrazinamidase pncA + ? Pyrazinamidase Sequencing
Ciproﬂoxacin DNA synthesis gyrA
gyrB
DNA gyrase
subunits A and B
(prinicipally)
PCR-SSCP,
microarray,
macroarray,
sequencing
PCR-SSSP, PCR single-strand conformation polymorphism.
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respectively. For the detection of rifampicin
resistance in specimens yielding M. tuberculosis
complex on culture, the Innolipa assay had con-
cordance, sensitivity, speciﬁcity, positive predic-
tive value and negative predictive value of 99.1%,
95.0%, 99.6%, 92.7%, and 99.7%, respectively
(Health Protection Agency National Mycobacte-
rium Reference Unit, unpublished data).
Non-commercial macroarrays have been devel-
oped and used successfully for the detection of
rifampicin and isoniazid resistance in cultures
[23,104,105]. In a sample of 233 isolates from
patients in Russia, 46.5% possessed mutations in
both the rpoB and katG (or inhA) genes. Results
from macroarrays demonstrated overall concor-
dance with resistance deﬁned phenotypically for
95.4% and 90.4% of isolates with rifampicin and
isoniazid resistance, respectively [104].
Other molecular drug resistance detection
methods
PCR single-strand conformation polymorphism
analysis can be performed using either a manual
or an automated system. A radioactive detection
system is often used, but silver-staining now offers
a sensitive alternative. Single-stranded DNA folds
into a complex tertiary structure, the shape of
which is dependent on the DNA sequence. If two
single strands of DNA differ by one or more bases,
i.e., a mutation, they will fold into structures with
different mobilities on a polyacrylamide gel, and
this can be used to detect the mutation [89]. Tests
for drug resistance and viability determination
have been developed, based on mRNA detection
following RT-PCR [108,109] and the use of molec-
ular beacons [110–112].
NOVEL PHENOTYPIC METHODS
Jacobs et al. [113] showed that drug susceptibility
could be assessed by measuring the production
of photons produced by viable mycobacteria
infected with phages expressing the ﬁreﬂy
luciferase gene. Untreated mycobacteria, or
drug-resistant mycobacteria in the presence of
the corresponding drugs, continue to express
luciferase, which catalyses the reaction of luciferin
with ATP to generate photons of light. Death of
mycobacteria leads to cessation of light produc-
tion. This approach has the advantage that
knowledge of the underlying genetic basis of
resistance is not required. Screening of novel anti-
mycobacterial drugs would also be simpliﬁed
using this technique. Recent research has reduced
the cost of this technique by the development of
the ‘Bronx Box’, involving a microtitre plate
format with a photographic ﬁlm detection system
[114]. Research to increase the sensitivity of the
assay and to reduce the capital costs is currently
ongoing.
An alternative approach, the ‘phage ampliﬁed
biologically’ (PhaB) assay, has been described for
the diagnosis and detection of drug resistance
[115,116]. This approach utilises skills and
resources that are readily available within the
diagnostic laboratory, without a need for expen-
sive luminometers. The PhaB assay can be used
for the diagnosis of M. tuberculosis in patient
samples, as well as for direct drug susceptibility
testing of strains isolated previously by conven-
tional culture. The concept of the method is
simple. In the ﬁrst step, a test culture or sample
is inoculated with mycobacteriophage. If viable
mycobacteria are present in the sample, they
become infected with mycobacteriophage. Subse-
quently, the mycobacteriophages remaining out-
side the mycobacteria are inactivated by a speciﬁc
chemical treatment, whereas those inside the
mycobacteria are protected. The protected myco-
bacteriophages then replicate within viable bacilli,
and eventually cause the host cells to lyse and
release the new generation of mycobacteriophag-
es. The released mycobacteriophages are plated
on a lawn of the rapidly growing related organ-
ism Mycobacterium smegmatis. The mycobacterio-
phages infect and replicate in this related
organism and, after overnight incubation, are
detected as clear areas of lysis or plaques in the
turbid growth of the M. smegmatis lawn. The
procedure is potentially rapid and simple, taking
as little as 48 h, compared with the weeks
required for conventional culture. The assay has
been calculated to detect 10–100 resistant myco-
bacteria ⁄mL of sample, which is at least as
sensitive as conventional culture. The assay
involves the use of simple equipment and, as
the assay proceeds, the number of viable infec-
tious M. tuberculosis cells declines, so that the
assay actually becomes safer as it continues. In a
recent evaluation, the assay correctly assigned
and identiﬁed 8 ⁄ 8 multiple drug-resistant
and 1 ⁄ 1 rifampicin-resistant, isoniazid-suscepti-
ble isolates. When used to test susceptibility to
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isoniazid, the PhaB assay correctly identiﬁed
15 ⁄ 17 (88.2%) isoniazid-resistant, rifampicin-sus-
ceptible isolates, and 17 ⁄ 21 (81%) isoniazid-sus-
ceptible isolates. The results can be obtained in as
little as 2 days from receipt of a patient sample
[115,116]. Correlation with the resistance ratio
method for streptomycin, ethambutol and pyraz-
inamide has been reported to be 96%, 88% and
87%, respectively [116]. These assays have now
been commercialised [117]. Other simpler and
inexpensive assays involving the use of dyes, e.g.,
Alamar blue and 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyl-tetrazolium bromide, have also shown
promise [118,119].
CONCLUSIONS
Methods for drug susceptibility testing of
M. tuberculosis have evolved over several dec-
ades. They are currently performed in specia-
lised centres in most European countries, as they
are technically demanding, require appropriate
isolation facilities, and can be difﬁcult to inter-
pret. The absolute concentration, resistance ratio
and proportion methods can all give accurate
results, provided that they are carefully quality-
controlled and standardised (the results from the
WHO Global Programme on Drug Resistance in
Tuberculosis indicated the problems of repro-
ducibility that occur when inexperienced labora-
tories perform drug susceptibility testing or
modify methods without a clear understanding
of the needs for standardisation and quality
control). Novel automated rapid culture and
molecular methods have been evaluated at large
reference centres and in multicentre collabora-
tions, with great success being demonstrated for
rifampicin and isoniazid testing, and some suc-
cess for other ﬁrst- and second-line drugs.
Drug susceptibility testing for ﬁrst-line drugs
is recommended for all new cases, with speci-
mens taken: (i) before initiating treatment; (ii) if
the patient continues to be culture-positive after
2–3 months; and (iii) if there is a history of
previous TB treatment (a major risk-factor for
drug resistance). Individual circumstances may
dictate additional testing. Accuracy is more
important than speed, and drug susceptibility
test results should be done by a small number
of well-equipped, experienced laboratories that
participate and perform well in an international
drug susceptibility testing quality assessment
scheme. The WHO Supranational Laboratory
Quality Control Network offers the greatest
global coverage, and assesses participating labo-
ratories for their ability to identify isoniazid,
rifampicin, ethambutol and streptomycin resis-
tance correctly.
Across Europe, early identiﬁcation of mycobac-
terial growth as ‘M. tuberculosis complex’ (princi-
pally M. tuberculosis and Mycobacterium bovis) and
testing for rifampicin resistance should be the
initial priorities, as rifampicin resistance invali-
dates standard 6-month short-course chemother-
apy and is a useful marker in most countries
for MDRTB. For patients with MDRTB, or for
individuals who are genuinely unable to tolerate
ﬁrst-line therapy, second-line therapy should be
instituted. There remains a need to standardise
second-line drug resistance testing, and such
testing should be performed only at the national
reference laboratories in western and central
European countries, because of the relatively
small number of cases and the concomitant
difﬁculty of maintaining testing proﬁciency in
multiple centres performing small numbers of
tests. This argument also holds for smaller eastern
European countries, e.g., the Baltic States, where
overall case numbers are small, but additional
qualiﬁed centres will be needed for the largest
countries in eastern Europe. There is a need to
further develop international EQA for second-line
drug susceptibility testing in order to complement
existing schemes for ﬁrst-line drugs.
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